Amgen's experimental drug may slow thyroid cancer, study finds July 3 (Bloomberg) -- Amgen Inc.'s experimental cancer drug motesanib blunted or reversed growth of thyroid tumors in a small study of patients with the most-serious stage of the disease.In the two-year study of 93 people with advanced...
Affymax wavers on forecast of Hematide approval NEW YORKShares of Affymax Inc.fluctuated wildly Wednesday after an analyst predicted success for the company's drug candidate Hematide as a treatment for anemia caused by kidney disease.Robert W.
Baird & Co.
analyst Christopher...
Affymax wavers on forecast of Hematide approval Shares of Affymax Inc.fluctuated wildly Wednesday after an analyst predicted success for the company's drug candidate Hematide as a treatment for anemia caused by kidney disease.
Robert W.
Baird & Co.
analyst Christopher Raymond...
Analyst sees 2011 approval and $800 million in sales for Affymax drug, but shares wobble - 2:07 p.m.NEW YORK (AP) - Shares of Affymax Inc.
fluctuated wildly Wednesday after an analyst predicted success for the company's drug candidate Hematide as a treatment for anemia caused by kidney disease.
Robert W.
Baird & Co....
Analyst sees 2011 approval and $800 million in sales for Affymax drug, but shares wobble - 2:07 p.m.NEW YORK (AP) - Shares of Affymax Inc.
fluctuated wildly Wednesday after an analyst predicted success for the company's drug candidate Hematide as a treatment for anemia caused by kidney disease.
Robert W.
Baird & Co....
Affymax wavers on forecast of Hematide approval NEW YORK - Shares of Affymax Inc.fluctuated wildly Wednesday after an analyst predicted success for the company's drug candidate Hematide as a treatment for anemia caused by kidney disease.
Robert W.
Baird & Co.
analyst...
Affymax wavers on forecast of Hematide approval NEW YORK (AP) - Shares of Affymax Inc.fluctuated wildly Wednesday after an analyst predicted success for the company's drug candidate Hematide as a treatment for anemia caused by kidney disease.
Robert W.
Baird & Co.
analyst...
Affymax wavers on forecast of Hematide approval Robert W.Baird & Co.
analyst Christopher Raymond predicted sales of Hematide could peak at $800 million.
He believes investors are overlooking the drug's prospects because it is an erythopoesis-stimulating agent, like Amgen Inc.'s...
Affymax wavers on forecast of Hematide approval NEW YORK (AP) -- Shares of Affymax Inc.fluctuated wildly Wednesday after an analyst predicted success for the company's drug candidate Hematide as a treatment for anemia caused by kidney disease.Robert W.
Baird & Co.
analyst...
Next Generation Protein Engineering and Drug Design - Strategies to boost efficacy and improve drug delivery - New Research Report on Companies and Markets Refer to a friend companiesandmarkets.com 2008-07-02 13:31:17 - www.companiesandmarkets.com adds new report - Next Generation Protein Engineering and Drug Design - Strategies to boost...
Health Winners & Losers: Myriad Genetics Pharma stocks outpaced the broader indices at the start of the July-Fourth week, amid a handful of regulatory news and prescription data.One stock on the decline, however, was Myriad GeneticsMYGN, which said Monday that a late-stage study...
FDA MedWatch - March 2008 Safety-Related Labeling Changes Posted -The March 2008 posting includes 50 drug products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and PATIENT PACKAGE INSERTS, and MEDICATION ES.The...
[external] Health Winners & Losers: Myriad Genetics Pharma stocks outpaced the broader indices at the start of the July-Fourth week, amid a handful of regulatory news and prescription data.One stock on the decline, however, was Myriad GeneticsMYGN, which said Monday that a late-stage study...
Health Winners & Losers: Myriad Genetics Pharma stocks outpaced the broader indices at the start of the July-Fourth week, amid a handful of regulatory news and prescription data.One stock on the decline, however, was Myriad GeneticsMYGN, which said Monday that a late-stage study...
20 Compounds That Defined Biotech As we know all too well, the course of a drug candidates clinical development is almost never smooth, and can often be pitted with unanticipated obstacles.Yet, despite this, many drugs manage to not only receive the FDAs blessing, but...
Key Challenges and Issues facing the Blood Disorders Market Analysis and Forecasts Report to 2013 Chapter 1: Executive Summary Chapter 2: Blood Diseases and their Treatments 2.1 Functions of Blood 2.1.1 Haemopoiesis 2.1.2 Haemostasis 2.2 Anaemia 2.2.1 Iron Deficiency 2.2.2 Anaemia of Chronic Disease 2.2.3 Megaloblastic Anaemia 2.2.4...
IMS: Global biotech sales up 12.5% in 2007 The biotech drug market grew by 12.5% to more than $75 billion in 2007, according to an IMS Health report.In 2006 the biotech market grew by 18.2%, to roughly $65 billion.
Profits last year were driven in large part by 22 biotech...
Centocor burnishes J&J's biotech cred Since becoming part of Johnson & Johnson in 1999, Horsham-based Centocor may not be as visible as when it was an independent company.But Centocor continues to have a huge impact on the Philadelphia region and the biotechnology...
Centocor helps J&J climb the biotech ranks Answer: Amgen, Genentech and everyone else.Would you believe me if I told you that Johnson & Johnson was No.
Market researcher IMS Health this week released data that shows the New Brunswick, N.J?
company is the worlds third...
For Biotechs, a bright future with challenges At the first day of BIO 2008 conference I met with Murry Aitken, Senior VP of Healthcare Insight at IMS Health.IMS just released a report on the.
Global biologic sales increased 12.5 percent in 2007 to more than $75 billion; that's...
Live from BIO: For Biotechs, a bright future with challenges At the first day of BIO 2008 conference I met with Murry Aitken, Senior VP of Healthcare Insight at IMS Health.IMS just released a report on the.
Global biologic sales increased 12.5 percent in 2007 to more than $75 billion; that's...
Live From Bio: Follow-on Biologics No matter what you call them -- biosimilars, biogenerics, generic biologics, follow-on biologics -- copycat versions of biologic drugs are a hot topic in both the biotech industry and Congress.Anytime you get drug innovators and those...
Amgen will suffer as a consequence of recent safety warnings concerning Aranesp and Epogen restricting General/Amgen-Inc-PharmaVita ..Introduction This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector.
The profile encompasses global company strategy, portfolio and pipeline analysis...
Sector Snap: Biotech outpaces pharma cousins 6:41 PM ET The number of biotechnology-based blockbuster drugs on the market skyrocketed in 2007, as more drug companies focused research and marketing attention on the cell-based technology.On Tuesday, IMS Health, which tracks the...
Davita spent $1.2 million lobbying in first quarter on kidney dialysis reimbursement WASHINGTON (AP) - Davita Inc., which operates kidney dialysis centers, spent $1.2 million on lobbying in the first quarter, according to a recent disclosure form.The El Segundo, Calif.-based company lobbied on bills that control how the...
